ZYME Zymeworks Inc.

NEUTRAL Impact: 3/10 PRESS-RELEASE
Horizon days Filed Apr 16, 2026 Processed 1mo ago Wire GlobeNewswire
Press release: earnings
Latest settled — T+20d
ZYME ▼ -9.67% at T+20d
NEUTRAL call ✗ call lost -9.67% · α vs SPY -15.48% · entry $27.20 → $24.57
Next anchor: T+60d in 5w
Last close $23.93 (close Jun 8) · -12.02% from $27.20 entry
Entry anchored
Apr 16, 05:53 AM ET
via Databento tick
T+1d
+2.21%
call +2.21% · α +0.99%
$27.80
settled 8w ago
T+5d
+0.85%
call +0.85% · α -0.14%
$27.43
settled 7w ago
T+20d
-9.67%
call -9.67% · α -15.48%
$24.57
settled 27d ago
T+60d
call — · α —
in 5w

Price Chart

Loading chart...

Executive Summary

Zymeworks announced it will report Q1 2026 financial results on May 7, 2026, with no actual financials disclosed in this press release. The company missed consensus EPS by 444% in the prior quarter (Q4 2025), signaling ongoing profitability challenges. This notice is routine and provides no update on performance or guidance.

Actionable Insight

Traders should monitor the May 7 earnings call for updates on cash runway, pipeline progress, and any changes to revenue or expense outlook, especially given the significant prior-quarter miss.

Key Facts

  • Company to report Q1 2026 financial results on May 7, 2026, after market close
  • Conference call scheduled for 4:30 pm ET to discuss results and provide corporate update
  • No financial data released in this announcement
  • Q4 2025 EPS was $-0.55 vs. consensus of $-0.10, a 444.7% miss
  • Q4 2025 revenue was $34.9M, in line with analyst estimates

Financial Impact

No immediate financial impact from this filing; material impact expected on May 7 with full results

epsrevenueguidance

Risk Factors

  • Continued negative EPS and high R&D spend could pressure cash reserves
  • Lack of near-term commercial revenue increases reliance on partnerships and financing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3275119
8 reports for ZYME
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+60▲ +8.97%Mar 2, 2026
Filters
Rows
Reports for ZYME — sortable, filterable
Type Now
May 15, 2026
25d ago
3
NEUTRAL ★ 2/10
$24.43 $25.40▲ +3.97%▲ +2.35%$23.93 (−2.05%)
Apr 21, 2026
7w ago
Press Release
BULLISH ★ 8/10
$28.53 $27.65▼ −3.08%▼ −3.14%$23.93 (−16.12%)
Apr 17, 2026
7w ago
Press Release
BULLISH ★ 7/10
$27.80 $28.10▲ +1.08%▲ +0.52%$23.93 (−13.92%)
Apr 16, 2026
7w ago
Press Release
NEUTRAL ★ 3/10
$27.20 $27.43▲ +0.85%▼ −0.14%$23.93 (−12.02%)
Apr 10, 2026
8w ago
3
NEUTRAL ★ 3/10
$26.17 $27.85▲ +6.42%▲ +3.12%$23.93 (−8.56%)
Mar 17, 2026
12w ago
Press Release
NEUTRAL ★ 3/10
$23.45 $24.23▲ +3.33%▲ +4.04%$23.93 (+2.05%)
Mar 2, 2026
14w ago
Press Release
BULLISH ★ 7/10
$23.31 $24.25▲ +4.03%▲ +5.24%$23.93 (+2.66%)
Mar 2, 2026
14w ago
Press Release
BULLISH ★ 8/10
$23.31 $24.25▲ +4.03%▲ +5.24%$23.93 (+2.66%)
Showing 8 of 8

US Market Status

Market Closed — Opens in 7h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access